Rvltn Bioscnc Financials
This page shows Rvltn Bioscnc (REVBW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Rvltn Bioscnc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rvltn Bioscnc carries a low D/E ratio of 0.31, meaning only $0.31 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.41, Rvltn Bioscnc holds $5.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Rvltn Bioscnc generates a -100.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -319.4% the prior year.
Rvltn Bioscnc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Rvltn Bioscnc generates $0.93 in operating cash flow (-$8.3M OCF vs -$8.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Rvltn Bioscnc's EBITDA was -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.8% from the prior year.
Rvltn Bioscnc reported -$8.9M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.
Rvltn Bioscnc earned $-23.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.7% from the prior year.
Cash & Balance Sheet
Rvltn Bioscnc held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.
Rvltn Bioscnc had 2M shares outstanding in fiscal year 2025. This represents an increase of 3539.1% from the prior year.
Margins & Returns
Rvltn Bioscnc's ROE was -100.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 218.8 percentage points from the prior year.
Capital Allocation
Rvltn Bioscnc invested $4.1M in research and development in fiscal year 2025. This represents an increase of 14.5% from the prior year.
REVBW Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.4M | N/A | $923K-30.0% | $1.3M+53.5% | $859K | N/A | $831K-40.4% | $1.4M |
| SG&A Expenses | $1.7M | N/A | $1.0M-10.8% | $1.1M-7.5% | $1.2M | N/A | $966K-14.3% | $1.1M |
| Operating Income | -$3.1M | N/A | -$1.9M+21.1% | -$2.5M-17.5% | -$2.1M | N/A | -$1.8M+28.8% | -$2.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | $0 | N/A | $0 | N/A | $0 | $0 |
| Net Income | -$3.0M | N/A | -$1.9M+22.0% | -$2.4M-19.2% | -$2.1M | N/A | -$2.2M+73.3% | -$8.4M |
| EPS (Diluted) | $-2.71 | N/A | $-1.77 | $-7.01+72.3% | $-25.34 | N/A | $-40.15+83.7% | $-246.27 |
REVBW Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.0M+29.9% | $11.6M-9.9% | $12.9M+138.3% | $5.4M+35.9% | $4.0M-40.0% | $6.6M-1.8% | $6.7M-45.1% | $12.3M |
| Current Assets | $14.2M+31.4% | $10.8M-15.7% | $12.8M+139.4% | $5.4M+36.5% | $3.9M-40.2% | $6.6M-1.4% | $6.7M-45.4% | $12.2M |
| Cash & Equivalents | $14.1M+31.9% | $10.7M-15.8% | $12.7M+145.6% | $5.2M+39.7% | $3.7M-43.0% | $6.5M-0.6% | $6.5M-45.8% | $12.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.1M-24.5% | $2.7M+46.8% | $1.9M+18.2% | $1.6M+44.0% | $1.1M-43.1% | $1.9M-52.9% | $4.1M-63.5% | $11.1M |
| Current Liabilities | $1.4M-29.1% | $2.0M+7.7% | $1.9M+18.2% | $1.6M+44.0% | $1.1M-43.1% | $1.9M-52.9% | $4.1M-63.5% | $11.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $13.0M+46.6% | $8.9M-19.5% | $11.0M+187.6% | $3.8M+32.8% | $2.9M-38.8% | $4.7M+76.1% | $2.7M+134.4% | $1.1M |
| Retained Earnings | -$52.4M-6.1% | -$49.4M-5.4% | -$46.9M-4.2% | -$45.0M-5.7% | -$42.6M-5.1% | -$40.5M-4.5% | -$38.8M-6.1% | -$36.5M |
REVBW Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-63.4% | -$2.0M-23.8% | -$1.6M+17.2% | -$1.9M+31.3% | -$2.8M+25.4% | -$3.7M+59.5% | -$9.3M-273.5% | -$2.5M |
| Capital Expenditures | $72K | N/A | N/A | N/A | N/A | -$18K-200.0% | $18K | $0 |
| Free Cash Flow | -$3.3M | N/A | N/A | N/A | N/A | -$3.8M+59.4% | -$9.3M-274.2% | -$2.5M |
| Investing Cash Flow | -$72K | N/A | N/A | N/A | N/A | $18K+200.0% | -$18K | $0 |
| Financing Cash Flow | $6.7M+16375.1% | -$41K-100.5% | $9.1M | N/A | N/A | $3.7M-1.5% | $3.7M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
REVBW Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -23.2% | N/A | -17.3%+46.6pp | -63.9%+7.3pp | -71.2% | N/A | -83.8%+651.8pp | -735.7% |
| Return on Assets | -20.0% | N/A | -14.8%+30.5pp | -45.3%+6.3pp | -51.7% | N/A | -33.3%+35.1pp | -68.4% |
| Current Ratio | 10.02+4.6 | 5.41-1.5 | 6.92+3.5 | 3.42-0.2 | 3.61+0.2 | 3.43+1.8 | 1.64+0.5 | 1.10 |
| Debt-to-Equity | 0.16-0.1 | 0.31+0.1 | 0.17-0.2 | 0.41+0.0 | 0.38-0.0 | 0.41-1.1 | 1.52-8.2 | 9.76 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Rvltn Bioscnc profitable?
No, Rvltn Bioscnc (REVBW) reported a net income of -$8.9M in fiscal year 2025.
What is Rvltn Bioscnc's EBITDA?
Rvltn Bioscnc (REVBW) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rvltn Bioscnc's return on equity (ROE)?
Rvltn Bioscnc (REVBW) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rvltn Bioscnc's operating cash flow?
Rvltn Bioscnc (REVBW) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Rvltn Bioscnc's total assets?
Rvltn Bioscnc (REVBW) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Rvltn Bioscnc spend on research and development?
Rvltn Bioscnc (REVBW) invested $4.1M in research and development during fiscal year 2025.
What is Rvltn Bioscnc's current ratio?
Rvltn Bioscnc (REVBW) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.
What is Rvltn Bioscnc's debt-to-equity ratio?
Rvltn Bioscnc (REVBW) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rvltn Bioscnc's return on assets (ROA)?
Rvltn Bioscnc (REVBW) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rvltn Bioscnc's cash runway?
Based on fiscal year 2025 data, Rvltn Bioscnc (REVBW) had $10.7M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rvltn Bioscnc's Piotroski F-Score?
Rvltn Bioscnc (REVBW) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rvltn Bioscnc's earnings high quality?
Rvltn Bioscnc (REVBW) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Rvltn Bioscnc?
Rvltn Bioscnc (REVBW) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.